| Welcome to FierceLifeSci Weekly Digest, your roundup of the biggest and most popular stories from each of our publications. | |
|
Featured Story | | | Thursday, March 29, 2018 While Shire’s shareholders Wednesday celebrated a possible Takeda bid, the Japanese drugmaker’s investors ran for the exits. Shares sank by 7% after Takeda said it was weighing a buyout, prompting more questions about a deal already raising some eyebrows. |
|
|
| This week's sponsor is Biotech Primer. | | | |
Top Stories Of The Week Monday, March 26, 2018 A phase 2 trial of Ablynx’s vobarilizumab in systemic lupus erythematosus has missed its primary endpoint. The setback tarnishes one of the drugs Sanofi is set to acquire through its $4.8 billion takeover of Ablynx. Tuesday, March 27, 2018 Turns out GlaxoSmithKline didn't walk away from Pfizer’s consumer health unit last week just because of its asking price. The British pharma giant had another buyout in mind—namely, a deal to take full control of its OTC venture with Novartis. Friday, March 23, 2018 Antibiotic-resistant bugs are on the rise, but gram-negative bacteria are a particularly tricky foe. Genentech scientists are pursuing a new approach, using an antibody to kill E. coli bacteria by blocking the enzyme BamA. Friday, March 23, 2018 A new report outlines 12 drugs launching this year that analysts expect will reel in big sales, with top drugmakers Roche, Johnson & Johnson, Gilead and more represented. Friday, March 23, 2018 For decades, scientific studies have hinged on showing a p-value of less than 0.05 as evidence that a study readout is genuine—but calls are growing for a new approach. Tuesday, March 27, 2018 Pfizer’s troubled Kansas fill-finish plant was evacuated for the second time in a year after a bomb threat at the manufacturing facility. Friday, March 23, 2018 Fred Moll’s Auris Health has won FDA approval for its surgical robotics platform. The nod clears the Intuitive Surgical founder’s latest venture to sell the device for use in bronchoscopic diagnostic and therapeutic procedures in lung cancer patients. Wednesday, March 28, 2018 Experts say technology is advancing to develop vaccines faster at a time of increasing emerging disease outbreaks. Wednesday, March 28, 2018 WuXi AppTec has received approval from the Chinese stock regulatory body to relist on the Shanghai Stock Exchange through an IPO of over $900 million, less than two months after the CRO giant submitted its revised prospectus. Resources Sponsored by: DocuSign Life science companies are experiencing a significant transformation in how they bring new products to market. |
